相关实验视频

Updated: Mar 3, 2026

Acupoint Catgut Embedding Therapy in Traditional Chinese Medicine for Managing Allergic Rhinitis

Acupoint Catgut Embedding Therapy in Traditional Chinese Medicine for Managing Allergic Rhinitis

Published on: December 20, 2024

在遗传性血管中治疗到目标的方法:欧洲委员会专家的共识

Mauro Cancian¹, Teresa Caballero², Isabelle Boccon-Gibod³

¹Department of Systems Medicine, University Hospital of Padua, Padua, Italy.

Frontiers in immunology

|March 2, 2026

概括

一个新的治疗到目标 (T2T) 算法通过设定个性化的目标来帮助管理遗传性血管 (HAE). 这种方法旨在通过优化治疗和有效监测进展来使患者的生活正常化.

科学领域:

过敏和免疫学过敏和免疫学
罕见疾病罕见疾病
临床实践指南临床实践指南

背景情况:

遗传性血管 (HAE) 是一种罕见的,不可预测的疾病,对患者的生活质量产生重大影响.
许多HAE患者无法实现推的治疗目标,即恢复正常生活.
目前的管理可能不总是符合世界过敏组织 (WAO) 和欧洲过敏和临床免疫学会 (EAACI) 的指导方针.

研究的目的:

开发和验证一种治疗到目标 (T2T) 算法,用于遗传性血管 (HAE) 管理.
促进WAO/EAACI指南在临床实践中的一致实施.
为优化青少年和成年人HAE治疗提供结构化,以患者为中心的战略.

主要方法:

一个欧洲专家委员会召开讨论指南的实施和确定T2T方法.
一个代的共识过程开发了一个T2T算法用于HAE管理.
该算法的可行性和清晰度通过对临床医生和患者代表的在线调查来评估.

主要成果:

开发了一个可视,实用的T2T算法来指导HAE管理.
该算法为启动长期预防 (LTP),设定个人目标和评估治疗计划提供了一个框架.
定期监测,评估疾病活性和优化治疗是实现目标和恢复正常生活的关键组成部分.

结论:

达成共识的T2T算法通过共享决策和个性化的目标来促进一致的HAE护理.
定期监测和治疗调整对于实现最佳患者结果至关重要.
HAE治疗的最终目标是使患者的生活正常化.

关键词:

处理到目标的目标.专家的共识专家的共识遗传性血管功能监控监控监控监控监控监控预防预防预防预防人们的生活质量.分享决策的决策.治疗目标治疗目标

更多相关视频

Testing Acetylcholine Followed by Adenosine for Invasive Diagnosis of Coronary Vasomotor Disorders

Testing Acetylcholine Followed by Adenosine for Invasive Diagnosis of Coronary Vasomotor Disorders

Published on: February 3, 2021

Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration

Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration

Published on: April 4, 2022

相关概念视频

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...

Atherosclerosis III: Management

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...

Pharmacogenomics: Identification of New Drug Targets

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...